Osteoporosis in Inflammatory Bowel Disease

被引：219

作者：

Ali, Tauseef ^{[1
,2
]}

Lam, David ^{[1
]}

Bronze, Michael S. ^{[1
]}

Humphrey, Mary Beth ^{[1
,3
]}

机构：

[1] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA

[2] Univ Oklahoma, Hlth Sci Ctr, Sect Digest Dis & Nutr, Oklahoma City, OK 73104 USA

[3] Univ Oklahoma, Hlth Sci Ctr, Sect Rheumatol Immunol & Allergy, Oklahoma City, OK 73104 USA

来源：

AMERICAN JOURNAL OF MEDICINE | 2009年 / 122卷 / 07期

关键词：

Inflammatory bowel disease; Osteopenia; Osteoporosis; BONE-MINERAL DENSITY; NECROSIS-FACTOR-ALPHA; VITAMIN-D STATUS; CROHNS-DISEASE; POSTMENOPAUSAL WOMEN; FRACTURE RISK; OSTEOBLAST DIFFERENTIATION; ORAL CORTICOSTEROIDS; KAPPA-B; TURNOVER;

D O I：

10.1016/j.amjmed.2009.01.022

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Osteoporosis commonly afflicts patients with inflammatory bowel disease, and many factors link the 2 states together. A literature review was conducted about the pathophysiology of osteoporosis in relation to inflammatory bowel disease. Screening guidelines for osteoporosis in general as well as those directed at patients with inflammatory bowel disease are reviewed, as are currently available treatment options. The purpose of this article is to increase physician awareness about osteopenia and osteoporosis occurring in patients with inflammatory bowel disease and to provide basic, clinically relevant information about the pathophysiology and guidelines to help them treat these patients in a cost-effective manner. Published by Elsevier Inc. The American Journal of Medicine (2009) 122, 599-604

引用

页码：599 / 604

页数：6

共 48 条

[1] Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease [J].

Abreu, MT ;

Geller, JL ;

Vasiliauskas, EA ;

Kam, LY ;

Vora, P ;

Martyak, LA ;

Yang, HY ;

Hu, B ;

Lin, YC ;

Keenan, G ;

Price, J ;

Landers, CJ ;

Adams, JS ;

Targan, SR .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 2006, 40 (01) :55-63

[2] Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity [J].

Adams, John S. ;

Hewison, Martin .

NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (02) :80-90

[3]

ALEXEEVA L, 1994, WHO TECH REP SER, V843, P1

[4]

[Anonymous], 2008, CLIN GUID PREV TREAT

[5] Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].

Barnes, PJ ;

Larin, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071

[6] Serum osteoprotegerin is increased in Crohn's disease: A population-based case control study [J].

Bernstein, CN ;

Sargent, M ;

Leslie, WD .

INFLAMMATORY BOWEL DISEASES, 2005, 11 (04) :325-330

[7] The pathophysiology of bone disease in gastrointestinal disease [J].

Bernstein, CN ;

Leslie, WD .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (08) :857-864

[8] AGA technical review on osteoporosis in gastrointestinal diseases [J].

Bernstein, CN ;

Leslie, WD ;

Leboff, MS .

GASTROENTEROLOGY, 2003, 124 (03) :795-841

[9] Reduced bone density in patients with inflammatory bowel disease [J].

Bjarnason, I ;

Macpherson, A ;

Mackintosh, C ;

BuxtonThomas, M ;

Forgacs, I ;

Moniz, C .

GUT, 1997, 40 (02) :228-233

[10]

Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98

← 1 2 3 4 5 →